EFPIA laments 'unfortunate' WHO decision on Lucentis
This article was originally published in Scrip
The World Health Organization's "unprecedented" decision not to put Novartis's Lucentis on its Essential Medicines List (EML) for wet AMD, while retaining an unlicensed drug (Roche's Avastin) on the list, sends out a "very unfortunate signal" to industry and regulators, says Richard Bergström, director general of the European industry federation EFPIA.
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.